KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Invested Capital (2018 - 2025)

Historic Invested Capital for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $3.7 billion.

  • Takeda Pharmaceutical's Invested Capital fell 9298.85% to $3.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $15.0 billion, marking a year-over-year decrease of 7160.24%. This contributed to the annual value of $75.2 billion for FY2025, which is 1053.28% down from last year.
  • Takeda Pharmaceutical's Invested Capital amounted to $3.7 billion in Q4 2025, which was down 9298.85% from $52.1 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Invested Capital registered a high of $92.7 billion during Q1 2021, and its lowest value of $3.7 billion during Q4 2025.
  • For the 5-year period, Takeda Pharmaceutical's Invested Capital averaged around $55.0 billion, with its median value being $52.7 billion (2022).
  • Data for Takeda Pharmaceutical's Invested Capital shows a peak YoY increase of 129239.18% (in 2025) and a maximum YoY decrease of 9298.85% (in 2025) over the last 5 years.
  • Takeda Pharmaceutical's Invested Capital (Quarter) stood at $51.0 billion in 2021, then decreased by 7.23% to $47.3 billion in 2022, then rose by 4.23% to $49.3 billion in 2023, then rose by 6.91% to $52.7 billion in 2024, then plummeted by 92.99% to $3.7 billion in 2025.
  • Its Invested Capital was $3.7 billion in Q4 2025, compared to $52.1 billion in Q3 2025 and $51.2 billion in Q2 2025.